Efficacy of tolterodine versus solifenacin in relieving lower urinary tract symptoms caused by ureteral stents
返回论文页
|更新时间:2021-08-23
|
Efficacy of tolterodine versus solifenacin in relieving lower urinary tract symptoms caused by ureteral stents
Health Medicine Research and PracticeVol. 16, Issue 3, Pages: 46-50(2019)
作者机构:
1. 成都医学院第一附属医院泌尿外科
2. 成都医学院
作者简介:
基金信息:
DOI:
CLC:R699
Published:2019,
扫 描 看 全 文
Wang Pengqiao, Zheng Renyuan. Efficacy of tolterodine versus solifenacin in relieving lower urinary tract symptoms caused by ureteral stents. [J]. Health Medicine Research and Practice 16(3):46-50(2019)
DOI:
Wang Pengqiao, Zheng Renyuan. Efficacy of tolterodine versus solifenacin in relieving lower urinary tract symptoms caused by ureteral stents. [J]. Health Medicine Research and Practice 16(3):46-50(2019)DOI:
Efficacy of tolterodine versus solifenacin in relieving lower urinary tract symptoms caused by ureteral stents
Objective To compare the efficacy of tolterodine versus solifenacin in relieving lower urinary tract symptoms(LUTS)caused by ureteral stents(double J tube)
so as to provide evidence for clinical management.Methods Ninety-six patients with indwelling double J tube after ureteroscopic lithotripsy who were treated at a Chengdu hospital between January 2015 and December 2016 were included in this study.Based on a random number table
these patients were divided into the control group
tolterodine group
and solifenacin group
32 patients in each group.All Patients received oral levofolxacin(0.5 g
once daily)
those in the tolterodine group also received tolterodine tartrate(4 mg
once daily)
and those in the solifenacin group were treated with solifenacin succinate(5 mg
once daily)in addition to levofolxacin.At 4 weeks
the Ureteral Stent Symptom Questionnaire(USSQ)and WHO Quality of Life-Brief Scale(WHOQOL-BREF)were used to assess the LUTS and QOL
respectively.Meanwhile
adverse events were monitored during the study.Results The urinary frequency
urgency
incontinence
lumbago
abdominal pain
and urethralgia scores in USSQ were 3.15±1.82
3.52±1.37
0.68±0.25
2.38±1.58
2.63±1.47
and 1.45±1.36 in the control group
respectively;2.08±1.89
1.26±1.31
0.16±0.19
0.87±1.43
0.59±1.38
and 0.96±1.38 in the tolterodine group
respectively;and 2.14±1.87
1.35±1.25
0.18±0.21
0.98±1.68
0.67±1.27
and 0.94±1.31 in the solifenacin group
respectively.All of these scores were significantly lower in both the tolterodine group and the solifenacin group as compared with the control group(all P<0.05);but these scores were comparable between the tolterodine group and the solifenacin group(P>0.05).The scores of the physical and psychological domains in WHOQOL-BREF were14.91±2.65 and 14.85±2.45 in the control group
respectively;16.47±2.58 and 16.78±2.98 in the tolterodine group
respectively;and 16.24±2.47 and 16.98±2.34 in the solifenacin group
respectively.Both scores were significantly higher in the tolterodine group and the solifenacin group as compared with the control group(both P<0.05)
but similar between the tolterodine group and the solifenacin group(P>0.05).Conclusion Compared with levofolxacin alone
tolterodine or solifenacin combined with levofolxacin seems to be more effective in relieving LUTS caused by double J tube
such as urinary frequency
urgency
incontinence
lumbago
abdominal pain
and urethralgia
which may substantially improve the quality of life of these patients.When added to levofolxacin
tolterodine and solifenacin have comparable efficacy
both of which may be selected according to the specific clinical conditions.
关键词
托特罗定索利那新双J管下尿路症状生活质量
Keywords
TolterodineSolifenacinDouble J tubeLower urinary tract symptomsQuality of life